RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial AdvisorFair points.
For the safety signal, the safety data seems generally good for the number treated and given that it is a bladder instillation drug (rather than systemic) the true safety is likely to be reasonable compared to something intravenous.
Did you refer the most recent Swimmers plot? I find that a good visual.
One thing that led many of us here was the phase 1 b data. Are you familiar with that? It gives you a feel for the "potential" of the drug.
By way of recap, they treated 3 patients with full dose and full light intensity.
The 2 patients that were CRin the phase 1b had the following profiles.
patient 1
- 12 prior HCG treatment, 2 different tumour locations on the bladder wall.
patient 2
- 18 prior treatments, 3 different tumour locations on the bladder wall.
So the drug had to reach 5 different tumours and ablate them completely. It did so and those patients have stayed NMIBC free to 18 months. That was from one treatment at day 0.
While there are many cheerleaders and naysayers, most of us believe that a treatment that can do that in the phase 1b patients after only one treatment is probably worth more than 49 million CAD market cap.